on EUROBIO-SCIENTIFIC (EPA:ALERS)
Eurobio Scientific Gains Majority Stake Through EB Development
On 19 December 2024, Eurobio Scientific announced that EB Development now holds 88.9% of its capital, following a successful reopening of their offer. The offer attracted a total of 5,227,882 shares, including 644,911 additionally obtained after its reopening. Collaborating with NextStage AM and IK Partners, EB Development did not surpass the 90% threshold which allows for a squeeze-out, hence forgoing the additional price per share. Settlement is set for 23 December 2024.
Denis Fortier, Chairman and CEO, expressed confidence in boosting the company’s growth with NextStage and IK Partners. Eurobio Scientific is supported in its expansion strategy, notably shown in past actions like acquiring GenDx. Key shareholders and partners show unified support for Eurobio Scientific's future development phases.
NextStage's and IK Partners' involvement is expected to bolster Eurobio Scientific's leading position in the in vitro diagnostics market. They maintain commitment towards aiding entrepreneurial growth and transformation within the company.
R. H.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all EUROBIO-SCIENTIFIC news